ADVZ Trademark

Trademark Overview


On Friday, April 1, 2022, a trademark application was filed for ADVZ with the United States Patent and Trademark Office. The USPTO has given the ADVZ trademark a serial number of 97342609. The federal status of this trademark filing is REGISTERED as of Tuesday, September 5, 2023. This trademark is owned by Mercury Pharma Group Limited. The ADVZ trademark is filed in the Pharmaceutical Products category with the following description:

A full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines, and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus a...
advz

General Information


Serial Number97342609
Word MarkADVZ
Filing DateFriday, April 1, 2022
Status700 - REGISTERED
Status DateTuesday, September 5, 2023
Registration Number7154065
Registration DateTuesday, September 5, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 20, 2023

Trademark Statements


Goods and ServicesA full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines, and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus and instruments, and surgical implants comprised of human and animal tissue; all of the foregoing excluding anti-infective pharmaceutical preparations and excluding over the counter analgesic products or pain relief products

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 6, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMercury Pharma Group Limited
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressLondon EC4N7BL
GB

Party NameMercury Pharma Group Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLondon EC4N7BL
GB

Party NameMercury Pharma Group Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLondon EC4N7BL
GB

Trademark Events


Event DateEvent Description
Tuesday, September 5, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, September 5, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, June 20, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 20, 2023PUBLISHED FOR OPPOSITION
Wednesday, May 31, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, May 15, 2023LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, May 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 5, 2023EXAMINER'S AMENDMENT ENTERED
Friday, May 5, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, May 5, 2023EXAMINERS AMENDMENT E-MAILED
Friday, May 5, 2023EXAMINERS AMENDMENT -WRITTEN
Thursday, May 4, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 4, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 4, 2023ASSIGNED TO LIE
Thursday, February 2, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, January 24, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, January 24, 2023LETTER OF SUSPENSION E-MAILED
Tuesday, January 24, 2023SUSPENSION LETTER WRITTEN
Tuesday, January 24, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, January 24, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, January 24, 2023EXAMINERS AMENDMENT E-MAILED
Tuesday, January 24, 2023EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 18, 2023ASSIGNED TO EXAMINER
Wednesday, April 6, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 5, 2022NEW APPLICATION ENTERED